Alltracel Pharmaceuticals plc Alltracel's Nanopeutics subsidiary signs new Professional Wound Care technology development agreement with ConvaTec November 12, 2007: London, UK & Dublin, Ireland Alltracel Pharmaceuticals Plc., ("Alltracel" or "the Company"), (AIM:AP.L), the healthcare innovation group focused on oral care, wound care, cardiovascular health and dermal health markets, today announces that its Nanopeutics subsidiary has signed a collaborative technology development agreement with ConvaTec, a world-leading manufacturer of ostomy and wound care products with a 25-year heritage of caring for patients. ConvaTec has been working with Alltracel since November 2006, when the initial primary concept development agreement was announced with a professional wound care partner. As per the original agreement, today's new technology agreement will be funded by ConvaTec and its successful conclusion may lead to an exclusive royalty bearing license and supply agreement between both companies. As part of the development work under the previous agreement, Alltracel's healthcare services division (Alltracel Healthcare Services) was also contracted by ConvaTec to perform laboratory testing and analysis work. The extension of the collaboration between Alltracel and ConvaTec will also include similar laboratory testing and analysis work by Alltracel Healthcare Services. Alltracel's Chief Executive Officer, Tony Richardson commented: "We are very pleased to announce our continuing collaboration with ConvaTec. Our new agreement in the area of professional wound care product development further supports the strength of Alltracel's development work carried out to date for ConvaTec and we look forward to progressing the commercialisation of our professional wound care products in 2008 and beyond. The professional wound care area is an important market for us and we are happy to be collaborating with a partner of ConvaTec's caliber and heritage. Alltracel's Nanospider(TM) technology affords many possibilities in this sector and seeks to improve product performance and assist in the treatment of many patients." Michael J Lydon PhD, Vice President Global R&D in ConvaTec commented: "ConvaTec acknowledges the significant commercial opportunities that nanotechnology presents in the field of professional wound care. This agreement recognizes our continuing commitment to develop this technology to enhance products and offer improved wound care solutions for our patients." ENDS For Further Information Contact: Dublin: Karen Muldowney Alltracel: +353 1 235 2162 press@alltracel.com London: Deborah Scott Financial Dynamics: +44 207 831 3113 Notes to Editors: Alltracel, (AIM: AP.L) (www.alltracel.com) the Healthcare Innovation Group is focused on taking proprietary technology from research right through to commercialisation in the global healthcare market. Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a public company which listed on London's Alternative Investment Market in July 2001. With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel also has a wide network of research, development and manufacturing partners in Europe, Asia and North America. Alltracel operates via two main divisions Alltracel Healthcare Group and Alltracel Healthcare Technologies: Alltracel Healthcare Group is focused on the commercialisation effort behind proven innovative technologies and services for the global healthcare market. Alltracel Healthcare Group has a range of stake holdings, joint ventures and wholly owned business units operating in a variety of healthcare categories including Wound Care, Oral Care, Dermal Health and Cardiovascular Health. - Alltracel's specialist Oral Care subsidiary Synpart Limited (www.synpartlimited.com) with offices in the UK and Germany is the leading contract supply and manufacturing partner for the European private label inter-dental market and also partners with a number of leading oral care brands internationally. - Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o. (www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is dedicated to the commercialisation of Nanospider(TM)technology for the global healthcare market. - Alltracel Healthcare Services provides Scientific Research, Clinical Trial & Development Services for Healthcare companies seeking a step up in speed of Healthcare Innovation. Alltracel Healthcare Technologies specialises in innovation, research, development and the deployment of proprietary technology in the global healthcare market. Alltracel Healthcare Technologies has established a substantial intellectual property portfolio with patents in a number of healthcare applications areas such as Wound Care, Oral Care, Cardiovascular Health and Dermal Health. ConvaTec Information ConvaTec, a world-leading manufacturer of ostomy and wound care products with a heritage of caring about patients, is a Bristol-Myers Squibb Company (NYSE:BMY ). Bristol-Myers Squibb is a global pharmaceutical and related health care products company. ConvaTec's Wound Therapeutics(TM)franchise pursues a comprehensive approach that grounds our advanced science in the everyday realities of wound and skin care. The company's Chronic Care franchise develops innovative products and product-related services to help people with an ostomy get back to their everyday activities and live their lives to the fullest. For more information please visit www.convatec.com. Wound Therapeutics(TM)is a trademark of ConvaTec, a Division of E.R. Squibb & Sons, LLC m-doc(TM)& Phytopeutics(TM)are trademarks of Alltracel Pharmaceuticals plc. Nanospider(TM)and Nanopeutics(TM)are trademarks controlled by Nanopeutics s.r.o. This information is provided by RNS The company news service from the London Stock Exchange
Alltracel Pharmaceuticals Plc announces Nanopeutics Agreement
| Source: Alltracel Pharmaceuticals Plc
DUBLIN, IRELAND--(Marketwire - November 12, 2007) -